Kempner Capital Management Inc. lifted its holdings in shares of Merck & Company, Inc. (NYSE:MRK) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,653 shares of the company’s stock after buying an additional 173 shares during the quarter. Kempner Capital Management Inc.’s holdings in Merck & were worth $1,324,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Vigilant Capital Management LLC grew its position in shares of Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after buying an additional 250 shares during the period. Harbour Capital Advisors LLC acquired a new stake in shares of Merck & during the 1st quarter worth approximately $127,000. Pinnacle Bank acquired a new stake in shares of Merck & during the 1st quarter worth approximately $152,000. Dillon & Associates Inc. acquired a new stake in shares of Merck & during the 1st quarter worth approximately $206,000. Finally, Addison Capital Co acquired a new stake in shares of Merck & during the 1st quarter worth approximately $218,000. Institutional investors own 72.91% of the company’s stock.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/28/kempner-capital-management-inc-has-1-32-million-stake-in-merck-company-inc-mrk.html.

Several equities research analysts have recently commented on MRK shares. Zacks Investment Research cut shares of Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Cowen and Company reiterated a “hold” rating and set a $70.00 price target on shares of Merck & in a research report on Friday, September 1st. Credit Suisse Group reiterated a “buy” rating on shares of Merck & in a research report on Tuesday, June 13th. Jefferies Group LLC reiterated a “sell” rating and set a $52.00 price target on shares of Merck & in a research report on Sunday, August 20th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $74.00 price target (up previously from $70.00) on shares of Merck & in a research report on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company. Merck & has a consensus rating of “Hold” and an average target price of $70.00.

Shares of Merck & Company, Inc. (MRK) traded up 0.039% on Thursday, reaching $64.595. 1,859,322 shares of the company’s stock were exchanged. The stock has a market cap of $176.17 billion, a P/E ratio of 34.973 and a beta of 0.81. Merck & Company, Inc. has a 52-week low of $58.29 and a 52-week high of $66.80. The company’s 50 day moving average price is $63.52 and its 200-day moving average price is $63.69.

Merck & (NYSE:MRK) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.93 EPS. Equities analysts forecast that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.91%. The ex-dividend date is Thursday, September 14th. Merck &’s payout ratio is 76.11%.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.